Therapeutic Management of Congestive Heart FailureSecondary to Dilated Cardiomyopathy in a Male LabradorDog: A Case Report

Authors

  • Udipta Bhuyan Department of Veterinary Pharmacology and Toxicology, College of Veterinary Science, Assam Agricultural University, Khanapara, Guwahati, Assam-781022, India https://orcid.org/0009-0009-0078-7433
  • Anindita Sandilya Department of Veterinary Medicine, College of Veterinary Sciences and Animal Husbandry, Central Agricultural University, Selesih, Aizawl, Mizoram-796015, India

DOI:

https://doi.org/10.48165/ijvsbt.20.6.37

Keywords:

Dilated Cardiomyopathy, Congestive Heart Failure, Pimobendan

Abstract

 

Dilated cardiomyopathy (DCM) is characterized by significant systolic dysfunction and expansion of the  heart chambers (Oyama, 2015). In dogs, DCM is one of the  most prevalent acquired cardiovascular conditions. Since  idiopathic DCM accounts for the majority of cases in dogs,  most treatments are categorized as ‘‘Band-Aid therapies,’’  which temporarily relieve symptoms but don’t address the  underlying source of the illness (Sanderson, 2006). Without  any indication of heart symptoms, the concealed stage of this  illness is typified by structural or electrical alterations. The  main morphologic signs of systolic dysfunction are left and  rarely right ventricular dilatation in systole and later diastole.  Ventricular premature complexes are the most common  type of electrical abnormalities (Wess et al., 2017). Clinical  indicators of congestive heart failure (CHF), such as elevated  respiratory rate, dyspnoea, coughing, or exercise intolerance,  are what define the overt stage of the condition (Friederich et  al., 2020). The present report describes a case of congestive  heart failure secondary to dilated cardiomyopathy in a  Labrador dog and its successful therapeutic management. 

Downloads

Download data is not yet available.

Author Biography

  • Udipta Bhuyan, Department of Veterinary Pharmacology and Toxicology, College of Veterinary Science, Assam Agricultural University, Khanapara, Guwahati, Assam-781022, India

    Department of Veterinary Pharmacology and Toxicology

References

Alvarez, A.M., & Mukherjee, D. (2011). Liver abnormalities in cardiac diseases and heart failure. International Journal of Angiology, 20(3), 135-142.

De Morais, H.A., & Schwartz, D.S. (2005). Pathophysiology of heart failure. In: Textbook of Veterinary Internal Medicine, Ed: Elsevier Sanders, Missouri, pp. 914-939.

Fitton, A., & Brogden, R.N. (1994). Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure. Drugs Aging, 4(5), 417-441.

Friederich, J., Seuß, A.C., & Wess, G. (2020). The role of atrial fibrillation as a prognostic factor in Doberman pinschers with dilated cardiomyopathy and congestive heart failure. The Veterinary Journal, 264, 105535.

Jeyaraja, K., Yamini, S.H., & Chandrasekaran, D. (2019). A retrospective analysis of dilated cardiomyopathy in Labrador retrievers. Journal of Animal Research, 9(5), 707-714.

Kumari, K.N., Reddy, B.S., Lakshmi, N.D., & Kumar, R.V. (2011). Congestive heart failure (CHF) in dogs - A report of 2 cases. Intas Polivet, 12(2), 268-270.

Oyama, M.A. (2015). Canine cardiomyopathy. In: Manual of Canine and Feline Cardiology. 5th edn., Ed: St. Louis, Missouri: Elsevier, pp 141-151.

Padalkar, M.A. (2012). Doppler studies on transvalvular blood flow dynamics in dilated cardiomyopathy of dogs. M.V.Sc. Thesis. Maharashtra Animal and Fishery Sciences University, Nagpur, India.

Rajamohan, S., Janarthanan, H.L., Chandrasekar, M., & Jeyaraja, K. (2018). Diagnostic evaluation and therapeutic management of dilated cardiomyopathy (DCM) in a Labrador retriever. The Pharma Innovation Journal, 7(6), 509-511.

Reina-Doreste, Y., Stern, J.A., Keene, B.W., Tou, S.P., Atkins, C.E., DeFrancesco, T.C., Ames, M.K., Hodge, T.E., & Meurs, K.M. (2014). Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure. Journal of the American Veterinary Medical Association, 245(5), 534-539.

Sanderson, S.L. (2006).Taurine and carnitine in canine cardiomyopathy. Veterinary Clinics: Small Animal Practice, 36(6), 1325-1343.

Silverberg, D., Wexler, D., Blum, M., Schwartz, D., & Iaina, A. (2004). The association between congestive heart failure and chronic renal disease. Current Opinion in Nephrology and Hypertension, 13(2), 163-170.

Silverberg, D.S., Wexler, D., Iaina, A., Steinbruch, S., Wollman, Y., & Schwartz, D. (2006). Anaemia, chronic renal disease and congestive heart failure - the cardio renal anemia syndrome: The need for cooperation between cardiologists and nephrologists. International Urology and Nephrology, 38, 295-310.

Swathi, S., Ajithkumar, S., Vishnurahav, R.B., & Pillai, U.N. (2020). Therapeutic management of dilated Cardiomyopathy in a labrador retriever dog. Journal of Indian Veterinary Association, 18(3), 68-71.

Velhankar, R.D. (2013). Two dimensional echocardiographic studies on dilated cardiomyopathy in dog, Ph.D.Thesis. Maharashtra Animal and Fishery Sciences University, Nagpur, India.

Wess, G., Domenech, O., Dukes-McEwan, J., Haggstrom, J., & Gordon, S. (2017). European society of veterinary cardiology screening guidelines for dilated cardiomyopathy in Doberman Pinschers. Journal of Veterinary Cardiology, 19, 405-415.

Downloads

Published

2024-11-05

How to Cite

Bhuyan, U., & Sandilya, A. (2024). Therapeutic Management of Congestive Heart FailureSecondary to Dilated Cardiomyopathy in a Male LabradorDog: A Case Report. Indian Journal of Veterinary Sciences and Biotechnology, 20(6), 178–181. https://doi.org/10.48165/ijvsbt.20.6.37